The purpose of this research is to test the effectiveness of an experimental drug combination
for people with metastatic castration-resistant prostate cancer (mCRPC).
The names of the study drugs involved in this study are:
- Telaglenastat (CB-839)
- Talazoparib
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Calithera Biosciences, Inc Pfizer Prostate Cancer Foundation